AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.64
-0.68 (-6.01%)
Apr 28, 2026, 4:00 PM EDT - Market closed

AgomAb Therapeutics NV Cash Flow Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2019 2018 - 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '19 2018 - 2017
Net Income
-62.55-46.27-11.39-8.14-
Upgrade
Depreciation & Amortization
0.220.310.10.02-
Upgrade
Stock-Based Compensation
5.361.072.162.21-
Upgrade
Other Operating Activities
4.83-0.66-19.58-14.47-
Upgrade
Change in Accounts Payable
2.36-0.233.692.95-
Upgrade
Change in Unearned Revenue
0.75-0.4-0.581.45-
Upgrade
Change in Other Net Operating Assets
-2.7-0.661.01-2.99-
Upgrade
Operating Cash Flow
-51.74-46.83-24.59-18.97-
Upgrade
Capital Expenditures
-0-0.68---
Upgrade
Cash Acquisitions
-3---4.59-
Upgrade
Investment in Securities
-30-40-40-
Upgrade
Investing Cash Flow
-33-0.6840-44.59-
Upgrade
Long-Term Debt Issued
---0.14-
Upgrade
Long-Term Debt Repaid
-0.34-0.16-0.1-0.72-
Upgrade
Net Debt Issued (Repaid)
-0.34-0.16-0.1-0.58-
Upgrade
Issuance of Common Stock
-97.0679.8738.39-
Upgrade
Other Financing Activities
--0.13-0.45-0.17-
Upgrade
Financing Cash Flow
-0.3496.7679.3237.63-
Upgrade
Foreign Exchange Rate Adjustments
0.05-0.2---
Upgrade
Miscellaneous Cash Flow Adjustments
-0---
Upgrade
Net Cash Flow
-85.0449.0694.73-25.92-
Upgrade
Free Cash Flow
-51.75-47.5-24.59-18.97-
Upgrade
Free Cash Flow Per Share
-95.63-1900.12-983.68-758.68-
Upgrade
Cash Interest Paid
-0.010.020.04-
Upgrade
Cash Income Tax Paid
-000-
Upgrade
Levered Free Cash Flow
-29.77-16.51-49.9--
Upgrade
Unlevered Free Cash Flow
-29.68-16.47-49.88--
Upgrade
Change in Working Capital
0.41-1.284.121.41-
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.